GlassScriptPhysician profile
Dean Horacio Trantham
NPI 1740778513
$2,760.50
in general payments reported to CMS, 2019-2025
27 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.80 · 2020: $15.29 · 2021: $407 · 2022: $821 · 2023: $902 · 2024: $392 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,505.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $649.84 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $447.12 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $218.19 | 2022-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $178.01 | 2021-2023 | Mounjaro |
| Dexcom, INC. | $160.23 | 2022-2023 | Dexcom G7 Gss (161) |
| Pfizer INC. | $122.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $115.05 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $109.90 | 2022 | |
| Nestle Healthcare Nutrition INC. | $96.81 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $76.08 | 2023-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $73.96 | 2022-2023 | |
| Abbott Laboratories | $73.35 | 2023 | Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $62.55 | 2021-2022 | |
| Amgen INC. | $53.89 | 2021-2023 | Otezla, Repatha |
| Astellas Pharma US INC | $48.04 | 2023-2024 | Veozah |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.48 | 2023 | Xifaxan |
| Edwards Lifesciences Corporation | $41.42 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $40.94 | 2022-2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $21.09 | 2022 | |
| Lucid Diagnostics INC. | $20.44 | 2024 | |
| Daiichi Sankyo INC. | $20.22 | 2024 | Injectafer |
| Esperion Therapeutics, INC. | $16.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.89 | 2023 | Tradjenta, Synjardy |
| Exact Sciences Corporation | $15.56 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $14.57 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.28 | 2021 | |
| Merck Sharp & Dohme LLC | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Trantham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.